{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:15:36Z","timestamp":1779380136845,"version":"3.53.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00894-025-06508-3","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:01:55Z","timestamp":1758783715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discovery of a potent ROR1 inhibitor using \u03bcs-scale MD simulations, wt-metadynamics, and absolute binding free energy calculations"],"prefix":"10.1007","volume":"31","author":[{"given":"Shradheya R. R.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Rameshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrakant Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"11","key":"6508_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"JS Brown","year":"2023","unstructured":"Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ (2023) Updating the definition of cancer. Mol Cancer Res 21(11):1142\u20131147. https:\/\/doi.org\/10.1158\/1541-7786.MCR-23-0411","journal-title":"Mol Cancer Res"},{"key":"6508_CR2","unstructured":"WHO. Global cancer burden growing, amidst mounting need for services. 2024; Available from: https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services."},{"issue":"1","key":"6508_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY (2024) Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther 9(1):175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"6508_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X (2019) Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2(2):141\u2013160. https:\/\/doi.org\/10.20517\/cdr.2019.10","journal-title":"Cancer Drug Resist"},{"issue":"16","key":"6508_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21037\/atm-21-1948","volume":"9","author":"L Zhu","year":"2021","unstructured":"Zhu L, Jiang M, Wang H, Sun H, Zhu J, Zhao W, Fang Q, Yu J, Chen P, Wu S et al (2021) A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Ann Transl Med 9(16):1351. https:\/\/doi.org\/10.21037\/atm-21-1948","journal-title":"Ann Transl Med"},{"issue":"3","key":"6508_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","volume":"4","author":"ZN Lei","year":"2023","unstructured":"Lei ZN, Tian Q, Teng QX, Wurpel JND, Zeng L, Pan Y, Chen ZS (2023) Understanding and targeting resistance mechanisms in cancer. MedComm 4(3):e265. https:\/\/doi.org\/10.1002\/mco2.265","journal-title":"MedComm"},{"issue":"1","key":"6508_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6(1):201. https:\/\/doi.org\/10.1038\/s41392-021-00572-w","journal-title":"Signal Transduct Target Ther"},{"key":"6508_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032645","author":"HN Abramson","year":"2023","unstructured":"Abramson HN (2023) Recent advances in the applications of small molecules in the treatment of multiple myeloma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24032645","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6508_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.apsb.2023.12.010","volume":"14","author":"F Wang","year":"2024","unstructured":"Wang F, Fu K, Wang Y, Pan C, Wang X, Liu Z, Yang C, Zheng Y, Li X, Lu Y et al (2024) Small-molecule agents for cancer immunotherapy. Acta Pharm Sin B 14(3):905\u2013952. https:\/\/doi.org\/10.1016\/j.apsb.2023.12.010","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"6508_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","volume":"35","author":"M Talpaz","year":"2021","unstructured":"Talpaz M, Kiladjian JJ (2021) Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia 35(1):1\u201317. https:\/\/doi.org\/10.1038\/s41375-020-0954-2","journal-title":"Leukemia"},{"issue":"4","key":"6508_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/2040620715586527","volume":"6","author":"AB Duenas-Perez","year":"2015","unstructured":"Duenas-Perez AB, Mead AJ (2015) Clinical potential of pacritinib in the treatment of myelofibrosis. Ther Adv Hematol 6(4):186\u2013201. https:\/\/doi.org\/10.1177\/2040620715586527","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"6508_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/17474086.2022.2098105","volume":"15","author":"C Saha","year":"2022","unstructured":"Saha C, Harrison C (2022) Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib. Expert Rev Hematol 15(7):583\u2013595. https:\/\/doi.org\/10.1080\/17474086.2022.2098105","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"6508_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.tibs.2022.04.011","volume":"47","author":"JB Sheetz","year":"2022","unstructured":"Sheetz JB, Lemmon MA (2022) Looking lively: emerging principles of pseudokinase signaling. Trends Biochem Sci 47(10):875\u2013891. https:\/\/doi.org\/10.1016\/j.tibs.2022.04.011","journal-title":"Trends Biochem Sci"},{"key":"6508_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.942500","volume":"10","author":"K Riegel","year":"2022","unstructured":"Riegel K, Vijayarangakannan P, Kechagioglou P, Bogucka K, Rajalingam K (2022) Recent advances in targeting protein kinases and pseudokinases in cancer biology. Front Cell Dev Biol 10:942500. https:\/\/doi.org\/10.3389\/fcell.2022.942500","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"6508_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4155\/fmc-2016-0207","volume":"9","author":"DP Byrne","year":"2017","unstructured":"Byrne DP, Foulkes DM, Eyers PA (2017) Pseudokinases: update on their functions and evaluation as new drug targets. Future Med Chem 9(2):245\u2013265. https:\/\/doi.org\/10.4155\/fmc-2016-0207","journal-title":"Future Med Chem"},{"issue":"7","key":"6508_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-019-0018-3","volume":"18","author":"JE Kung","year":"2019","unstructured":"Kung JE, Jura N (2019) Prospects for pharmacological targeting of pseudokinases. Nat Rev Drug Discov 18(7):501\u2013526. https:\/\/doi.org\/10.1038\/s41573-019-0018-3","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"6508_CR17","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2021014760","volume":"140","author":"TJ Kipps","year":"2022","unstructured":"Kipps TJ (2022) ROR1: an orphan becomes apparent. Blood 140(14):1583\u20131591. https:\/\/doi.org\/10.1182\/blood.2021014760","journal-title":"Blood"},{"issue":"3","key":"6508_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109834","volume":"37","author":"F Shi","year":"2021","unstructured":"Shi F, Mendrola JM, Sheetz JB, Wu N, Sommer A, Speer KF, Noordermeer JN, Kan ZY, Perry K, Englander SW et al (2021) ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes. Cell Rep 37(3):109834. https:\/\/doi.org\/10.1016\/j.celrep.2021.109834","journal-title":"Cell Rep"},{"key":"6508_CR19","doi-asserted-by":"publisher","unstructured":"Sheetz JB, Mathea S, Karvonen H, Malhotra K, Chatterjee D, Niininen W, Perttila R, Preuss F, Suresh K, Stayrook SE et al (2020) Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Mol Cell. 79(3):390\u2013405 e7. https:\/\/doi.org\/10.1016\/j.molcel.2020.06.018","DOI":"10.1016\/j.molcel.2020.06.018"},{"issue":"12","key":"6508_CR20","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D et al (2017) Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res 23(12):3061\u20133071. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2083","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6508_CR21","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","volume":"36","author":"EM Ghia","year":"2022","unstructured":"Ghia EM, Rassenti LZ, Choi MY, Quijada-Alamo M, Chu E, Widhopf GF 2nd, Kipps TJ (2022) High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. Leukemia 36(6):1609\u20131618. https:\/\/doi.org\/10.1038\/s41375-022-01543-y","journal-title":"Leukemia"},{"issue":"2","key":"6508_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3250","volume":"42","author":"N Mouawad","year":"2024","unstructured":"Mouawad N, Ruggeri E, Capasso G, Martinello L, Visentin A, Frezzato F, Trentin L (2024) How receptor tyrosine kinase-like orphan receptor 1 meets its partners in chronic lymphocytic leukemia. Hematol Oncol 42(2):e3250. https:\/\/doi.org\/10.1002\/hon.3250","journal-title":"Hematol Oncol"},{"issue":"1","key":"6508_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13058-024-01782-0","volume":"26","author":"RA Shatsky","year":"2024","unstructured":"Shatsky RA, Batra-Sharma H, Helsten T, Schwab RB, Pittman EI, Pu M, Weihe E, Ghia EM, Rassenti LZ, Molinolo A et al (2024) A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced\/unresectable or metastatic Her2-negative breast cancer. Breast Cancer Res 26(1):32. https:\/\/doi.org\/10.1186\/s13058-024-01782-0","journal-title":"Breast Cancer Res"},{"issue":"6","key":"6508_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198038","volume":"13","author":"AH Daneshmanesh","year":"2018","unstructured":"Daneshmanesh AH, Hojjat-Farsangi M, Ghaderi A, Moshfegh A, Hansson L, Schultz J, Vagberg J, Bystrom S, Olsson E, Olin T et al (2018) A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS ONE 13(6):e0198038. https:\/\/doi.org\/10.1371\/journal.pone.0198038","journal-title":"PLoS ONE"},{"key":"6508_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102238","author":"A Ghaderi","year":"2022","unstructured":"Ghaderi A, Zhong W, Okhovat MA, Aschan J, Svensson A, Sander B, Schultz J, Olin T, Osterborg A, Hojjat-Farsangi M et al (2022) A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of mantle cell lymphoma (MCL) cells. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14102238","journal-title":"Pharmaceutics"},{"issue":"3","key":"6508_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/jha2.232","volume":"2","author":"A Ghaderi","year":"2021","unstructured":"Ghaderi A, Okhovat MA, Wikanthi LSS, Svensson A, Palma M, Schultz J, Olin T, Osterborg A, Mellstedt H, Hojjat-Farsangi M (2021) A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1(+) CLL cells. EJHaem 2(3):498\u2013502. https:\/\/doi.org\/10.1002\/jha2.232","journal-title":"EJHaem"},{"key":"6508_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041148","author":"A Ghaderi","year":"2023","unstructured":"Ghaderi A, Okhovat MA, Lehto J, De Petris L, Manouchehri Doulabi E, Kokhaei P, Zhong W, Rassidakis GZ, Drakos E, Moshfegh A et al (2023) A small molecule targeting the intracellular tyrosine kinase domain of ROR1 (KAN0441571C) induced significant apoptosis of non-small cell lung cancer (NSCLC) cells. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15041148","journal-title":"Pharmaceutics"},{"key":"6508_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8060170","author":"A Ghaderi","year":"2020","unstructured":"Ghaderi A, Daneshmanesh AH, Moshfegh A, Kokhaei P, Vagberg J, Schultz J, Olin T, Harrysson S, Smedby KE, Drakos E et al (2020) ROR1 is expressed in diffuse large B-cell lymphoma (DLBCL) and a small molecule inhibitor of ROR1 (KAN0441571C) induced apoptosis of lymphoma cells. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines8060170","journal-title":"Biomedicines"},{"issue":"5","key":"6508_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217789","volume":"14","author":"N Fultang","year":"2019","unstructured":"Fultang N, Illendula A, Chen B, Wu C, Jonnalagadda S, Baird N, Klase Z, Peethambaran B (2019) PLoS ONE 14(5):e0217789. https:\/\/doi.org\/10.1371\/journal.pone.0217789","journal-title":"PLoS ONE"},{"key":"6508_CR30","doi-asserted-by":"publisher","first-page":"1243763","DOI":"10.3389\/fcell.2023.1243763","volume":"11","author":"SRR Gupta","year":"2023","unstructured":"Gupta SRR, Ta TM, Khan M, Singh A, Singh IK, Peethambaran B (2023) Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer. Front Cell Dev Biol 11:1243763. https:\/\/doi.org\/10.3389\/fcell.2023.1243763","journal-title":"Front Cell Dev Biol"},{"key":"6508_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151614","volume":"758","author":"B Sharma","year":"2025","unstructured":"Sharma B, Purohit R (2025) Enhanced sampling simulations to explore Himalayan phytochemicals as potential phosphodiesterase-1 inhibitor for neurological disorders. Biochem Biophys Res Commun 758:151614. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151614","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"6508_CR32","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41598-022-05875-8","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Ishchenko A, Zhang W, Razavi A, Langley D (2022) A highly accurate metadynamics-based dissociation free energy method to calculate protein-protein and protein-ligand binding potencies. Sci Rep 12(1):2024. https:\/\/doi.org\/10.1038\/s41598-022-05875-8","journal-title":"Sci Rep"},{"issue":"8","key":"6508_CR33","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1021\/acs.jpcb.8b10341","volume":"123","author":"LS Dodda","year":"2019","unstructured":"Dodda LS, Tirado-Rives J, Jorgensen WL (2019) Unbinding dynamics of non-nucleoside inhibitors from HIV-1 reverse transcriptase. J Phys Chem B 123(8):1741\u20131748. https:\/\/doi.org\/10.1021\/acs.jpcb.8b10341","journal-title":"J Phys Chem B"},{"issue":"9","key":"6508_CR34","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1021\/acs.jcim.0c00276","volume":"60","author":"KJ Cutrona","year":"2020","unstructured":"Cutrona KJ, Newton AS, Krimmer SG, Tirado-Rives J, Jorgensen WL (2020) Metadynamics as a postprocessing method for virtual screening with application to the pseudokinase domain of JAK2. J Chem Inf Model 60(9):4403\u20134415. https:\/\/doi.org\/10.1021\/acs.jcim.0c00276","journal-title":"J Chem Inf Model"},{"issue":"7","key":"6508_CR35","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47(7):1739\u20131749. https:\/\/doi.org\/10.1021\/jm0306430","journal-title":"J Med Chem"},{"issue":"4","key":"6508_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrd1364","volume":"3","author":"P Kirkpatrick","year":"2004","unstructured":"Kirkpatrick P (2004) Gliding to success. Nat Rev Drug Discov 3(4):299\u2013299. https:\/\/doi.org\/10.1038\/nrd1364","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"6508_CR37","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41596-021-00676-1","volume":"17","author":"H Fu","year":"2022","unstructured":"Fu H, Chen H, Blazhynska M, Coderc G, de Lacam E, Szczepaniak F, Pavlova A, Shao X, Gumbart JC, Dehez F, Roux B et al (2022) Accurate determination of protein:ligand standard binding free energies from molecular dynamics simulations. Nat Protoc 17(4):1114\u20131141. https:\/\/doi.org\/10.1038\/s41596-021-00676-1","journal-title":"Nat Protoc"},{"issue":"1","key":"6508_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1):235\u2013242. https:\/\/doi.org\/10.1093\/nar\/28.1.235","journal-title":"Nucleic Acids Res"},{"key":"6508_CR39","doi-asserted-by":"publisher","unstructured":"Rustagi V, Gupta SRR, Singh A, Singh IK (2024) Beyond trial and error: Leveraging advanced software for Therapeutic discovery. Chemical Biology Letters. 12(1):1251. https:\/\/doi.org\/10.62110\/sciencein.cbl.2025.v12.1251","DOI":"10.62110\/sciencein.cbl.2025.v12.1251"},{"issue":"3","key":"6508_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27(3):221\u2013234. https:\/\/doi.org\/10.1007\/s10822-013-9644-8","journal-title":"J Comput Aided Mol Des"},{"issue":"5","key":"6508_CR41","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcc.21666","volume":"32","author":"T Hou","year":"2011","unstructured":"Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the molecular mechanics\/Poisson Boltzmann surface area and molecular mechanics\/generalized born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem 32(5):866\u2013877. https:\/\/doi.org\/10.1002\/jcc.21666","journal-title":"J Comput Chem"},{"key":"6508_CR42","doi-asserted-by":"crossref","unstructured":"Bowers KJ, Chow DE, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL, Kolossvary I, Moraes MA, Sacerdoti FD et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. in SC '06: Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing. 2006.","DOI":"10.1109\/SC.2006.54"},{"issue":"12","key":"6508_CR43","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1021\/acs.jctc.8b00391","volume":"14","author":"B Knapp","year":"2018","unstructured":"Knapp B, Ospina L, Deane CM (2018) Avoiding false positive conclusions in molecular simulation: the importance of replicas. J Chem Theory Comput 14(12):6127\u20136138. https:\/\/doi.org\/10.1021\/acs.jctc.8b00391","journal-title":"J Chem Theory Comput"},{"key":"6508_CR44","doi-asserted-by":"publisher","unstructured":"Editorial (2023) Reliability and reproducibility checklist for molecular dynamics simulations. Commun Biol. 6(1):268. https:\/\/doi.org\/10.1038\/s42003-023-04653-0","DOI":"10.1038\/s42003-023-04653-0"},{"key":"6508_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1070080","volume":"9","author":"AU Danazumi","year":"2022","unstructured":"Danazumi AU, Balogun EO (2022) Microsecond-long simulation reveals the molecular mechanism for the dual inhibition of falcipain-2 and falcipain-3 by antimalarial lead compounds. Front Mol Biosci 9:1070080. https:\/\/doi.org\/10.3389\/fmolb.2022.1070080","journal-title":"Front Mol Biosci"},{"issue":"4","key":"6508_CR46","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1021\/acs.jcim.0c00057","volume":"60","author":"H Guterres","year":"2020","unstructured":"Guterres H, Im W (2020) Improving protein-ligand docking results with high-throughput molecular dynamics simulations. J Chem Inf Model 60(4):2189\u20132198. https:\/\/doi.org\/10.1021\/acs.jcim.0c00057","journal-title":"J Chem Inf Model"},{"key":"6508_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.149300","volume":"1847","author":"V Rustagi","year":"2025","unstructured":"Rustagi V, Rameshwari R, Kumar Singh I (2025) Identification of potential inhibitors for MAP4K4 in glaucoma using meta-dynamics-based dissociation free energy calculation. Brain Res 1847:149300. https:\/\/doi.org\/10.1016\/j.brainres.2024.149300","journal-title":"Brain Res"},{"issue":"4","key":"6508_CR48","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1021\/acs.jpcb.6b11696","volume":"121","author":"K Moritsugu","year":"2017","unstructured":"Moritsugu K, Terada T, Kidera A (2017) Free-energy landscape of protein-ligand interactions coupled with protein structural changes. J Phys Chem B 121(4):731\u2013740. https:\/\/doi.org\/10.1021\/acs.jpcb.6b11696","journal-title":"J Phys Chem B"},{"key":"6508_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-62703-658-0_11","volume":"1084","author":"CC David","year":"2014","unstructured":"David CC, Jacobs DJ (2014) Principal component analysis: a method for determining the essential dynamics of proteins. Methods Mol Biol 1084:193\u2013226. https:\/\/doi.org\/10.1007\/978-1-62703-658-0_11","journal-title":"Methods Mol Biol"},{"issue":"2","key":"6508_CR50","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRevLett.100.020603","volume":"100","author":"A Barducci","year":"2008","unstructured":"Barducci A, Bussi G, Parrinello M (2008) Well-tempered metadynamics: a smoothly converging and tunable free-energy method. Phys Rev Lett 100(2):020603. https:\/\/doi.org\/10.1103\/PhysRevLett.100.020603","journal-title":"Phys Rev Lett"},{"issue":"10","key":"6508_CR51","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1021\/acs.jcim.3c00013","volume":"63","author":"W Chen","year":"2023","unstructured":"Chen W, Cui D, Jerome SV, Michino M, Lenselink EB, Huggins DJ, Beautrait A, Vendome J, Abel R, Friesner RA et al (2023) Enhancing hit discovery in virtual screening through absolute protein-ligand binding free-energy calculations. J Chem Inf Model 63(10):3171\u20133185. https:\/\/doi.org\/10.1021\/acs.jcim.3c00013","journal-title":"J Chem Inf Model"},{"issue":"5","key":"6508_CR52","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1021\/acs.jcim.1c00269","volume":"61","author":"H Fu","year":"2021","unstructured":"Fu H, Chen H, Cai W, Shao X, Chipot C (2021) BFEE2: automated, streamlined, and accurate absolute binding free-energy calculations. J Chem Inf Model 61(5):2116\u20132123. https:\/\/doi.org\/10.1021\/acs.jcim.1c00269","journal-title":"J Chem Inf Model"},{"issue":"13","key":"6508_CR53","doi-asserted-by":"publisher","first-page":"10655","DOI":"10.1021\/acs.jmedchem.4c00175","volume":"67","author":"D Luo","year":"2024","unstructured":"Luo D, Qiu X, Zheng Q, Ming Y, Pu W, Ai M, He J, Peng Y (2024) Discovery of novel receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors for cancer treatment. J Med Chem 67(13):10655\u201310686. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00175","journal-title":"J Med Chem"},{"issue":"11","key":"6508_CR54","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 29(11):1859\u20131865. https:\/\/doi.org\/10.1002\/jcc.20945","journal-title":"J Comput Chem"},{"issue":"1","key":"6508_CR55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(1):33. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5","journal-title":"J Mol Graph"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-025-06508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-025-06508-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-025-06508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:45:51Z","timestamp":1760759151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-025-06508-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6508"],"URL":"https:\/\/doi.org\/10.1007\/s00894-025-06508-3","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a computational (in-silico) study that does not involve experiments on human participants, human data, animals, or biological samples. Therefore, no ethical approval or clearance is required for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}